Real-world safety and effectiveness of nusinersen, a treatment for spinal muscular atrophy, in 401 Japanese patients: results from an interim analysis of post-marketing surveillance

被引:5
作者
Tachibana, Yosuke [1 ]
Takasaki, Sakura [1 ]
Hoshino, Misuzu [1 ]
Makioka, Haruki [1 ]
Jin, Mingshou [1 ]
机构
[1] Biogen Japan, Tokyo, Japan
关键词
Spinal muscular atrophy; nusinersen; post-marketing surveillance; safety; effectiveness; SHAM CONTROL; INFANT; MOUSE;
D O I
10.1080/00207454.2022.2095270
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Purpose: Nusinersen is an antisense oligonucleotide for the treatment of spinal muscular atrophy (SMA). A post-marketing surveillance (PMS) has been ongoing (August 2017-August 2025) in all patients in Japan who received intrathecal nusinersen in real-world clinical settings. We report the interim analysis results of safety and effectiveness. Methods: This interim analysis was conducted using data collected from 401 patients whose case report forms were obtained at least once by 30 May 2020. Collected data included patient demographics and adverse events (AEs) for safety, and motor function assessments and Clinical Global Impressions of Improvement (CGI-I) for effectiveness. Results: All 401 patients were diagnosed with SMA and were included in the safety and effectiveness analysis (infantile-onset SMA [n = 126, 31.4%], later-onset SMA [n = 275, 68.6%]). The median duration of treatment was 330 days (range 1-823 days). The incidence proportion of AEs was 31.7% (37.3% in infantile-onset SMA and 29.1% in later-onset SMA). The most common AEs were headache (4.5%), pyrexia (4.2%), and pneumonia (3.7%). The incidence proportion of serious AEs was 11.5%. Nusinersen improved motor function scores and was assessed as 'effective' based on CGI-I in 99.7-100% of patients. Conclusions: This interim analysis of the PMS in Japanese patients treated with nusinersen found no new safety concerns, with the type of AEs consistent with the expected safety profile. The benefit-risk balance of nusinersen treatment remains favorable.
引用
收藏
页码:153 / 162
页数:10
相关论文
共 19 条
  • [1] Restoring SMN Expression: An Overview of the Therapeutic Developments for the Treatment of Spinal Muscular Atrophy
    Aslesh, Tejal
    Yokota, Toshifumi
    [J]. CELLS, 2022, 11 (03)
  • [2] Prognostic Factors and Treatment-Effect Modifiers in Spinal Muscular Atrophy
    Baranello, Giovanni
    Gorni, Ksenija
    Daigl, Monica
    Kotzeva, Anna
    Evans, Rachel
    Hawkins, Neil
    Scott, David A.
    Mahajan, Anadi
    Muntoni, Francesco
    Servais, Laurent
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (06) : 1435 - 1454
  • [3] MOTOR MILESTONE ASSESSMENT OF INFANTS WITH SPINAL MUSCULAR ATROPHY USING THE HAMMERSMITH INFANT NEUROLOGICAL EXAM-PART 2: EXPERIENCE FROM A NUSINERSEN CLINICAL STUDY
    Bishop, Kathie M.
    Montes, Jacqueline
    Finkel, Richard S.
    [J]. MUSCLE & NERVE, 2018, 57 (01) : 142 - 146
  • [4] A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity
    Cho, Sungchan
    Dreyfuss, Gideon
    [J]. GENES & DEVELOPMENT, 2010, 24 (05) : 438 - 442
  • [5] Proactive Compared With Passive Adverse Event Recognition: Calcium Channel Blocker-Associated Edema
    Chrysant, Steven G.
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2008, 10 (09) : 716 - 722
  • [6] An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials
    Darras, Basil T.
    Farrar, Michelle A.
    Mercuri, Eugenio
    Finker, Richard S.
    Foster, Richard
    Hughes, Steven G.
    Bhan, Ishir
    Farwell, Wildon
    Gheuens, Sarah
    [J]. CNS DRUGS, 2019, 33 (09) : 919 - 932
  • [7] Developmental milestones in type I spinal muscular atrophy
    De Sanctis, Roberto
    Coratti, Giorgia
    Pasternak, Amy
    Montes, Jacqueline
    Pane, Marika
    Mazzone, Elena S.
    Young, Sally Dunaway
    Salazar, Rachel
    Quigley, Janet
    Pera, Maria C.
    Antonaci, Laura
    Lapenta, Leonardo
    Glanzman, Allan M.
    Tiziano, Danilo
    Muntoni, Francesco
    Darras, Basil T.
    De Vivo, Darryl C.
    Finkel, Richard
    Mercuri, Eugenio
    [J]. NEUROMUSCULAR DISORDERS, 2016, 26 (11) : 754 - 759
  • [8] Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy
    Finkel, R. S.
    Mercuri, E.
    Darras, B. T.
    Connolly, A. M.
    Kuntz, N. L.
    Kirschner, J.
    Chiriboga, C. A.
    Saito, K.
    Servais, L.
    Tizzano, E.
    Topaloglu, H.
    Tulinius, M.
    Montes, J.
    Glanzman, A. M.
    Bishop, K.
    Zhong, Z. J.
    Gheuens, S.
    Bennett, C. F.
    Schneider, E.
    Farwell, W.
    De Vivo, D. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (18) : 1723 - 1732
  • [9] Optimality score for the neurologic examination of he infant at 12 and 18 months of age
    Haataja, L
    Mercuri, E
    Regev, R
    Cowan, F
    Rutherford, M
    Dubowitz, V
    Dubowitz, L
    [J]. JOURNAL OF PEDIATRICS, 1999, 135 (02) : 153 - 161
  • [10] Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
    Hua, Yimin
    Sahashi, Kentaro
    Hung, Gene
    Rigo, Frank
    Passini, Marco A.
    Bennett, C. Frank
    Krainer, Adrian R.
    [J]. GENES & DEVELOPMENT, 2010, 24 (15) : 1634 - 1644